Newer Study Shows Psilocybin Can Provide Relief from Depression

Psilocybin may just change the way we address mental health forever.

It may even revolutionize how major pharmaceutical giants tackle a good deal of mental health issues. After all, a recent study of 24 adults with major depression published in the journal JAMA Psychiatry found that two doses led to a large reduction in depression symptoms.

According to Alan Davis from the Johns Hopkins University School of Medicine, as quoted by New Atlas, "The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market."

"Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future 'gold-standard' placebo-controlled clinical trials," he added.

The U.S. is seeing broader support of psilocybin use, as well.

Just last week, Oregon became the first state to legalize psilocybin in a therapeutic setting. With Measure 109, the psilocybin movement is about overcoming depression, as noted by KATU 2 ABC. In addition, "An estimated 1 in every 5 adults in Oregon is coping with a mental health condition," 20 doctors and other health care workers wrote in the voters' pamphlet.

"We support Measure 109 because it provides a new treatment for many that might break through where others fall short."

With big progress being made, psilocybin could change mental health treatment for the better.

Better Plant Sciences (CSE: PLNT) (OTC: VEGGF) is Part of the Growing Psilocybin Story

Better Plant Sciences' majority owned subsidiary NeonMind Biosciences entered into a definitive agreement with Psygen Labs Inc. for the supply of psilocybin for NeonMind's planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety.

"Psilocybin is known to activate serotonin receptors," says Dr. William Panenka, lead scientific advisor to NeonMind. "As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings."

"Psygen's mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research," says Danny Motyka, CEO of Psygen Labs Inc. "We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem."

"Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics."

For more information, visit the company's website at https://betterplantsciences.com

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.

Contact Information:
2818047972
ty@lifewatermedia.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67961

News Provided by Newsfile via QuoteMedia

Better Plant Sciences CNX:PLNT VEGGF Cannabis Investing

Trulieve Partners with Black Buddha Cannabis to Launch Premium Products in Arizona and Pennsylvania

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing medical marijuana company in the U.S., today announces a partnership with Black Buddha Cannabis a purpose-driven and women-owned medical marijuana brand. The collaboration will introduce Black Buddha Cannabis products to Trulieve dispensaries in Arizona and Pennsylvania starting in October 2024 .

Black Buddha Cannabis, founded by Roz McCarthy , CEO of Soaring High Industries and Minorities for Medical Marijuana, brings a unique approach to the medical marijuana industry with a focus on wellness and healing. McCarthy, a 30+ year healthcare industry veteran and a 2018 honoree in High Times' 100 Most Influential People, launched Black Buddha Cannabis after a traumatic brain injury that transformed her life and inspired her to explore the therapeutic benefits of medical marijuana.

Products from Black Buddha's "BLYSS" and "DREAM" lines of premium medical marijuana flower will be available in Trulieve stores throughout Arizona and Pennsylvania starting Friday, October 4 . Black Buddha products are curated for a blissful experience by focusing on terpene profiles and enhanced therapeutic effects that cater to a balanced lifestyle.

"We are incredibly excited to bring Black Buddha Cannabis to the vibrant markets of Arizona and Pennsylvania ," says Black Buddha Cannabis Chief Executive Officer Roz McCarthy . "Our brand is deeply rooted in wellness, and our mission is to help people feel better, whether they are part of the adult-use or medical marijuana community. We believe everyone deserves access to products that enhance their well-being, and we're thrilled to offer our carefully curated flower lines to these new markets."

Trulieve's partnership with Black Buddha Cannabis marks a significant milestone in expanding the Company's product offerings and supporting brands that align with Trulieve's commitment to wellness, innovation, and quality. This collaboration is expected to resonate with customers who seek premium medical marijuana crafted with intention and care.

"We are excited to welcome Black Buddha Cannabis to our product lineup," said Trulieve's Chief Executive Officer Kim Rivers . "Roz's inspiring story and her brand's dedication to healing through medical marijuana align perfectly with Trulieve's mission to provide high-quality, purpose-driven products to our customers."

Arizona and Pennsylvania will serve as the target markets for the initial launch of the partnership, a collaboration that underscores Trulieve's ongoing commitment to offering high-quality and innovative products that cater to the diverse needs of its customers.

For more information on Black Buddha Cannabis, please visit BlackBuddha.co . Visit Trulieve.com to find store locations, sign up for updates and shop for products online.

About Black Buddha Cannabis
Black Buddha Cannabis establishes a new paradigm for the industry as a black-owned, environmentally conscious, wellness-focused, and social equity-driven brand. Black Buddha Cannabis' premiere lifestyle and wellness products will be found at leading dispensaries across the country through state-by-state brand partnerships with manufacturers, cultivators, and operators. Currently available in Ohio , Nevada and Massachusetts , Black Buddha Cannabis expects to have products available in New Jersey in January 2025 . To learn more about Black Buddha Cannabis please visit http://blackbuddha.co .

About Trulieve
Trulieve is an industry-leading, vertically integrated medical marijuana company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to medical marijuana, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-partners-with-black-buddha-cannabis-to-launch-premium-products-in-arizona-and-pennsylvania-302263424.html

SOURCE Trulieve Cannabis Corp.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2024/01/c1475.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Announces Upcoming Event Participation

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced planned event participation.

ATB Capital Markets 2024 Life Sciences Institutional Investor Conference, September 18, 2024 : Vice President of Investor Relations Christine Hersey will participate in investor meetings.
Benzinga Cannabis Capital Conference, October 8 - 9, 2024 : Chief Marketing Officer Gina Collins will participate in a panel discussion on Next-Gen Cannabis Retail on October 9th at 11:00 AM , and Vice President of Investor Relations Christine Hersey will participate in a VIP Roundtable discussion on Capital Markets and investor meetings.

Information about our events, links to events where available, and slide presentations can be found at: https://investors.trulieve.com/events

About Trulieve

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-upcoming-event-participation-302245660.html